Novel gelatin-adriamycin sustained drug release system for intravesical therapy of bladder cancer

Abstract

To reduce recurrence in the patients with bladder cancer after tumor removal through open surgery or transurethral resection, a form of gelatin-adriamycin sustained drug release system was developed and its release kinetics bothin vitro andin vivo, its efficacy in inhibiting BIU-87 bladder tumor cell growthin vitro and its safetyin vivo were studied. The results showed that this system controlled adriamycin release over a period of 21 daysin vitro and significantly inhibited BIU-87 cell growth. When this system was injected into rabbit bladder, it sustained adriamycin release for 12 days and the released drug could diffuse 1 cm around the injection point. No major complications were observed except minor acute nonspecific cystitis that could be tolerated well by the animals. This study suggests the possibility of applying this system locally in treating bladder cancer.

Keywords

bladder cancer / adriamycin / gelatin / sustained drug release

References

[1] JakseG, JungP. KraneR J, SirolyM B, FitzpatrickJ M. Superficial Bladder Cancer. Clinical Urology, 1994PhiladephiaJ. B. Lippincott Company645-661

[2] 1993, 14 (2):108

[3] Gabizon A, Sulkes N, Ben-Baruch Tet al. Exploratory clinical phase of limpsome-entrapped doxorubicin. J Cell Biochem, 1988, Suppl 12 B: 251

[4] DelgadoG, PotkulP K, TreatJ A, et al.. A phase I / II study of intraperitoneally administered doxorubicin entrapped in cardiolipid limpsomes in patients with ovarian cancer. Am J Obstet Gynecol, 1989, 160(4): 812-812

[5] KimS, TurkerM S, ChiE Y, et al.. Preparation of multivesicular liposomes. Biochmica et Biphysica Acta, 1983, 728: 339-339

[6] BalazsovitsJ A E, MayerL L D, BallyM B, et al.. Analysis of the effect of liposome encapuslation on the vesicant proterties, acute and cardiac toxicities, and anti-tumor efficacy of doxorubin. Cancer Chemother Pharmacol, 1989, 23: 81-81

[7] RahamnA, CarmichaelD, HarrisM, et al.. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardilipin liposomes. Cancer Research, 1986, 46: 2295-2295

[8] GlashanR W. Treatment of carcinoma in situ of the bladder with doxorubicin. Cancer Chemother Pharmacol, 1983, 11: 35-35

[9] MatsumuraY. Intravesical adriamycin chemotherapy in bladder cancer. Cancer Chemother Pharmacol, 1983, 11: 69-69

[10] BonoA V, BenventiC, CamianoG, et al.. Results of transurethral resection and intravesical doxorubicin proghylaxis in patients with T1G3 bladder cancer. Urology, 1994, 4(3): 329-329

[11] GekkerH. Controlled release of biologically active compounds from bioeodible polymers. Biomaterials, 1980, 1: 51-51